Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634842 · ClinicalTrials.gov registry record · Phase 4
Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily
A Phase 4 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 4
- Development phase
- 244
- Enrollment target
NCT00634842 is a Phase 4 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 244 participants.
The verdict
NCT00634842, a Phase 4 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 244 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America. The aim of this trial is to explore how different fasting blood glucose targets affect glucose control in patients with type 2 diabetes, when patients are empowered to do dose adjustments themselves.
Interventions
- DRUG insulin detemir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00634842
The ClinicalTrials.gov registry entry for NCT00634842 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which insulin detemir is the first listed.
NCT00634842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00634842 about?
NCT00634842 is a clinical study titled "Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily". This trial is conducted in the United States of America. The aim of this trial is to explore how different fasting blood glucose targets affect glucose control in patients with type 2 diabetes, when patients are empowered to do dose adjustments themselves.
What is the current status of trial NCT00634842?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 244 participants. The study started on 2008-02. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00634842?
The interventions under investigation include: insulin detemir (DRUG).
Who is sponsoring clinical trial NCT00634842?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.